Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
Heavy losses for Hikma Pharmaceuticals today as the stock fell by -€0.700 (-3.560%).
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | -3.560% | 4.334% | 3.050% | -7.404% | 9.432% | -23.571% | -35.369% |
| Viatris Inc. | -0.180% | -8.219% | -1.095% | 65.593% | 33.764% | 35.840% | 11.611% |
| Repligen Corp. | -0.780% | 9.888% | 13.019% | 48.133% | 1.384% | -9.045% | -32.800% |
| Opko Health Inc. | -0.840% | 8.182% | 4.386% | 13.010% | 9.154% | -26.334% | -62.114% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat
